Canaccord Genuity Maintains Buy on Orthofix Medical, Lowers Price Target to $13
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $18 to $13.
Stocks · News reference
Reported July 2, 2026: Orthofix Medical Says Medicare Will Restore Pre-May 18 Reimbursement Rates For Bone Growth Stimulators After CMS Reversal
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Orthofix shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
8-K filing — Orthofix Medical Inc. (OFIX)
Filed: 2026-08-05 AccNo: 0001193125-26-333817 Size: 30 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Orthofix Medical Raises FY2026 Sales Guidance from $838.000M-$848.000M to $845.000M-$855.000M vs $843.311M Est
Orthofix Medical (NASDAQ:OFIX) raises FY2026 sales outlook from $838.000 million-$848.000 million to $845.000 million-$855.000 million vs $843.311 million estimate.